Wall Street brokerages forecast that La Jolla Pharmaceutical (NASDAQ:LJPC) will post earnings per share of ($1.31) for the current quarter, Zacks reports. Two analysts have issued estimates for La Jolla Pharmaceutical’s earnings, with estimates ranging from ($1.61) to ($1.04). La Jolla Pharmaceutical posted earnings of ($2.22) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 41%. The firm is expected to report its next quarterly earnings report on Thursday, May 9th.
According to Zacks, analysts expect that La Jolla Pharmaceutical will report full year earnings of ($3.99) per share for the current fiscal year, with EPS estimates ranging from ($6.03) to ($1.51). For the next fiscal year, analysts anticipate that the firm will report earnings of ($3.20) per share, with EPS estimates ranging from ($4.93) to ($1.45). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover La Jolla Pharmaceutical.
La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Monday, March 4th. The biopharmaceutical company reported ($1.73) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.01. The business had revenue of $4.18 million for the quarter, compared to analyst estimates of $4.20 million. La Jolla Pharmaceutical had a negative return on equity of 223.23% and a negative net margin of 1,983.58%.
LJPC has been the topic of several research reports. BidaskClub raised La Jolla Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Monday, January 7th. ValuEngine downgraded La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Zacks Investment Research downgraded La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, December 28th. Cowen reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical in a report on Tuesday, March 5th. Finally, Jefferies Financial Group raised La Jolla Pharmaceutical from an “underperform” rating to a “hold” rating and reduced their price objective for the stock from $13.00 to $6.00 in a report on Monday, January 14th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $30.83.
NASDAQ LJPC traded down $0.02 during trading hours on Friday, reaching $7.15. 178,374 shares of the company’s stock were exchanged, compared to its average volume of 419,211. The firm has a market cap of $193.59 million, a PE ratio of -0.91 and a beta of 1.32. La Jolla Pharmaceutical has a one year low of $5.01 and a one year high of $38.39.
Several hedge funds have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in La Jolla Pharmaceutical during the 1st quarter worth $67,000. Metropolitan Life Insurance Co. NY raised its stake in La Jolla Pharmaceutical by 357.4% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,699 shares of the biopharmaceutical company’s stock worth $82,000 after buying an additional 6,797 shares during the period. Fox Run Management L.L.C. acquired a new stake in La Jolla Pharmaceutical during the 4th quarter worth $100,000. Jane Street Group LLC acquired a new stake in La Jolla Pharmaceutical during the 4th quarter worth $134,000. Finally, Paloma Partners Management Co acquired a new stake in La Jolla Pharmaceutical during the 4th quarter worth $206,000.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.